Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation of the Efficacy, Safety, and Tolerability of PF-04950615, in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects